During the last session, Cardiol Therapeutics Inc (NASDAQ:CRDL)’s traded shares were 0.48 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stock’s price was $1.46, reflecting an intraday gain of 7.35% or $0.1. The 52-week high for the CRDL share is $3.12, that puts it down -113.7 from that peak though still a striking 34.25% gain since the share price plummeted to a 52-week low of $0.96. The company’s market capitalization is $119.14M, and the average intraday trading volume over the past 10 days was 0.25 million shares, and the average trade volume was 365.93K shares over the past three months.
Cardiol Therapeutics Inc (CRDL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRDL has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Cardiol Therapeutics Inc (NASDAQ:CRDL) trade information
Cardiol Therapeutics Inc (CRDL) registered a 7.35% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.35% in intraday trading to $1.46, hitting a weekly high. The stock’s 5-day price performance is 20.66%, and it has moved by 14.06% in 30 days. Based on these gigs, the overall price performance for the year is 30.36%. The short interest in Cardiol Therapeutics Inc (NASDAQ:CRDL) is 0.81 million shares and it means that shorts have 1.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 81.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, CRDL is trading at a discount of -447.95% off the target high and -447.95% off the low.
Cardiol Therapeutics Inc (CRDL) estimates and forecasts
Statistics show that Cardiol Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Cardiol Therapeutics Inc (CRDL) shares have gone down -34.23% during the last six months, with a year-to-date growth rate less than the industry average at 0.00% against 16.80.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 16.52%. While earnings are projected to return -19.02% in 2025, the next five years will return -8.84% per annum.
CRDL Dividends
Cardiol Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cardiol Therapeutics Inc (NASDAQ:CRDL)’s Major holders
Cardiol Therapeutics Inc insiders own 3.91% of total outstanding shares while institutional holders control 9.51%, with the float percentage being 9.89%. TEJARA CAPITAL LTD is the largest shareholder of the company, while 50.0 institutions own stock in it. As of 2024-06-30, the company held over 1.72 million shares (or 2.5606% of all shares), a total value of $3.48 million in shares.
The next largest institutional holding, with 1.47 million shares, is of ADVISORSHARES INVESTMENTS LLC’s that is approximately 2.1811% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cardiol Therapeutics Inc (CRDL) shares are AdvisorShares Trust-AdvisorShares Pure Cannabis ETF and Fidelity NASDAQ Composite Index Fund . Data provided on Nov 30, 2024 indicates that AdvisorShares Trust-AdvisorShares Pure Cannabis ETF owns about 942.36 shares. This amounts to just over 1.14 percent of the company’s overall shares, with a $1.38 million market value. The same data shows that the other fund manager holds slightly less at 52.44, or about 0.06% of the stock, which is worth about $76555.0.
